appoints Drs. David Barnes (top left), Douglas Cowart (right) and Gary Schwartz (bottom left) to its newly formed clinical development group, to take the company’s cancer drug, PhG-alpha-1, through the process required to get approval to begin clinical trials in humans. Dr. Barnes, a physician and molecular biologist, has worked with industry and government in clinical development, regulation and safety of biologics since 2001. He is a former clinical evaluator of Health Canada’s biologics and genetic therapies directorate, and past head of its biotechnology products surveillance unit, marketed health products directorate. Dr. Barnes has served as PharmaGap’s director of clinical development and regulatory affairs since 2005. He will have overall responsibility for the program, reporting to company president Robert McInnis. Dr. Douglas Cowart, a pharmacologist, has over 25 years experience in clinical trials design and planning, with both FDA and international clinical trials experience in over 50 clinical studies. In his practice, Dr. Cowart has developed a consortium of medical, scientific, and regulatory consultants, which will be brought to bear on the project, as required. Dr. Gary Schwartz, chief, melanoma and sarcoma service for Sloan-Kettering’s department of medicine’s division of solid tumor oncology, has been working with the company since 2006. His numerous titles include member and attending physician at Memorial Sloan-Kettering Cancer Center and professor of medicine at Weill Medical College of Cornell University in New York.